Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.
about
Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of CardiologyRecent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsTestosterone Antagonizes Doxorubicin-Induced Senescence of Cardiomyocytes.Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?Protective Role of GPER Agonist G-1 on Cardiotoxicity Induced by Doxorubicin.Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats.Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase.The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice.The paradox of the first cycle of chemotherapy-transient improvement of contractility and diastolic function after the first cycle of anthracycline-based chemotherapy: a prospective clinical trial.Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production.Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective.Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine.Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity
P2860
Q26765793-0E3BD3DC-5632-4E23-A83A-B0DB40E6D4DFQ28087776-0B03C37E-4FD4-478C-8AE7-DE4D1EEA6DD8Q36877575-B0B60DEB-E93B-4FA4-9F11-213F3F9F59E9Q37131070-9F87CB61-BC1E-439F-995A-0765DCE382ECQ39410524-98FA1246-114E-4A4D-BE75-8A333FDDA235Q43151456-3B279970-0DE9-4A70-B9AA-8E277D8EE31DQ47115167-2D8B690A-AE13-4C87-AEE4-15E47D46A956Q47117911-9AB19494-5E96-47CF-8782-EF11A22BD558Q47567559-A42B8E75-BA95-4FD2-8A4C-73AEE9A57D8AQ50146298-7A3D4FAB-62ED-40F9-A1F0-0D1C16028330Q51093490-A3DF74FE-3A08-4705-9946-85F6340F12DFQ51760757-FFFB3C0D-0859-4C94-B581-4D0EEC7089D9Q52714655-0FB80232-AF3A-42D6-9106-35DE18224405Q55222160-CAF5FFF4-BCFA-4A77-BE75-9FE885C246B5Q58738740-8E7B1217-DD13-4637-AC91-B425C3447FAD
P2860
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.
description
2014 nî lūn-bûn
@nan
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.
@en
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.
@nl
type
label
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.
@en
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.
@nl
prefLabel
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.
@en
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.
@nl
P2093
P2860
P50
P356
P1476
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction
@en
P2093
Andrea Carpi
Antonella Arcari
Clemente Cipresso
Cristina Quintavalle
Giovanna Piscopo
Marika Campesan
Nicola Maurea
P2860
P304
P356
10.1002/EJHF.50
P50
P577
2014-04-01T00:00:00Z